Trimetazidine in Anti-Doping: Cases, Uses & Classification
Discover the key facts about Trimetazidine, including its involvement in doping cases, medical applications, and recent classification changes.
What is Trimetazidine used for?
Trimetazidine is used to prevent angina attacks and manage symptoms such as chest pain, jaw pain, and back pain associated with reduced blood flow to the heart. It is also utilized in treating vertigo, tinnitus, reduced vision, and visual field disturbances caused by blood vessel problems.
How many doping cases involve Trimetazidine?
The Anti-Doping Database has registered a total of 28 doping cases involving Trimetazidine.
Which countries have reported doping cases related to Trimetazidine?
Russia leads with 12 doping cases, followed by China with 3 cases, and Ukraine with 3 cases.
Which sports have reported doping cases related to Trimetazidine?
Track and Field has reported 7 doping cases, while Swimming and Rowing have reported 4 and 3 cases, respectively.
What are the sanctions for Trimetazidine-related doping cases?
Sanctions vary depending on the severity of the violation. The Anti-Doping Database shows that 12 individuals received a 4-year suspension, 5 individuals received a 2-year suspension, and 2 individuals received a 15-month suspension.
How does Trimetazidine work?
Trimetazidine is classified as a metabolic agent that affects the body's metabolism. It is believed to protect against myocardial ischaemia (reduced blood supply to the heart muscle) by increasing the breakdown rate of glucose.
What recent changes have occurred in Trimetazidine's classification?
Since the beginning of 2015, Trimetazidine has been reclassified. It was initially prohibited in-competition only until the end of 2014. It has been moved to the newly created sub-section S4.5.c as a modulator of cardiac metabolism.The information provided in this article was correct as of July 19, 2023
Sources:
- World Anti-Doping Agency (WADA) - wada-ama.org
- PubMed - Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions
- European Medicines Agency - Trimetazidine